keynote-040: groundbreaking results for pembrolizumab in head and neck cancer
Published 5 years ago • 1K plays • Length 4:03Download video MP4
Download video MP3
Similar videos
-
1:48
post hoc keynote-040 analysis: pembrolizumab for hnscc produces lasting immune effect
-
1:59
pembrolizumab in the treatment of head and neck cancer: is there more to the story?
-
7:03
pembrolizumab for frontline head and neck cancer: keynote-048 results
-
1:06
dr. cohen discusses the keynote-040 trial in head and neck cancer
-
3:08
improved survival, toxicity & qol with pembrolizumab in head and neck cancer
-
1:09
the future role of immunotherapy in head and neck cancers
-
3:35
is there a use for anti-pdl-1 antibodies in recurrent head and neck cancer?
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
0:39
predicting responses to immunotherapy in head and neck cancer
-
1:36
addition of an egfr/tgfβ inhibitor with pembrolizumab in head and neck cancer
-
2:12
unanswered questions in head and neck cancer
-
1:27
where to go next with pembrolizumab and other anti-pd-1 therapies in head and neck cancer
-
1:56
eftilagimod alpha and pembrolizumab in patients with squamous head and neck carcinoma
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
1:22
the extreme regimen for head and neck cancer
-
2:07
study results for nivolumab and pembrolizumab in head and neck cancer
-
5:30
#esmo21 expert video report on head and neck cancer
-
4:06
immunotherapy for head and neck cancer treatment
-
2:08
future directions for head and neck cancer